AIM
SRPT icon

AIA Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

AIA Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$18K Hold
128
– – ﹤0.01% 402
2020
Q2 		$21K Buy
+128
New +$17.4K ﹤0.01% 334

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AIA Investment Management's SRPT Position: Q3 2020 in Review

AIA Investment Management held its Sarepta Therapeutics (SRPT) position steady in Q3 2020 at 128 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #402.

AIA Investment Management first reported a position in SRPT in Q2 2020 and has held it in 2 quarters since. The position peaked at $21K in Q2 2020. 403 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

  • AIA Investment Management held 128 shares of Sarepta Therapeutics worth $18K as of Q3 2020.
  • AIA Investment Management left its Sarepta Therapeutics share count unchanged in Q3 2020.
  • Sarepta Therapeutics made up ﹤0.01% of AIA Investment Management's portfolio in Q3 2020, its #402 holding.
  • AIA Investment Management first reported a position in Sarepta Therapeutics in Q2 2020 and has held it in 2 quarters since.
  • AIA Investment Management's Sarepta Therapeutics position peaked at $21K in Q2 2020.
  • 403 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on AIA Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.